{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:42:14Z","timestamp":1792392134986,"version":"4.4.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Waldenstr\u00f6m's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma. It has an overall incidence of 2.5\/million\/year. The median age at diagnosis is 63 years. The clinical manifestations are hepatomegaly (20%), splenomegaly (15%), and lymphadenopathy (15%). The most common symptom is fatigue related to a normochromic, normocytic anemia, and the median hemoglobin value at diagnosis is 10 gm\/dl. All patients with Waldenstr\u00f6m's macroglobulinemia have a circulating tumor marker, the monoclonal IgM protein. Occasionally high levels of the IgM monoclonal protein can produce a hyperviscosity syndrome manifested by oronasal bleeding. Occasionally retinal hemorrhage or serious neurologic complications, such as somnolence or coma, may occur. The most important prognostic factors are hemoglobin, age, weight loss, and a cryoglobulin. Therapy has included alkylating agents, particularly chlorambucil, purine nucleoside analogs such as fludarabine or cladribine, and most recently the use of rituximab. The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated.<\/jats:p>","DOI":"10.1634\/theoncologist.5-1-63","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"63-67","source":"Crossref","is-referenced-by-count":94,"title":["Waldenstr\u00f6m's Macroglobulinemia"],"prefix":"10.1093","volume":"5","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,2,1]]},"reference":[{"key":"2021122206320555800_R1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0025-6196(12)65225-2","article-title":"The spectrum of IgM monoclonal gammopathy in 430 cases","volume":"62","author":"Kyle","year":"1987","journal-title":"Mayo Clin Proc"},{"key":"2021122206320555800_R2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1378\/chest.88.2.297","article-title":"Two cases of pulmonary Waldenstr\u00f6m's macroglobulinemia","volume":"88","author":"Kobayashi","year":"1985","journal-title":"Chest"},{"key":"2021122206320555800_R3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007611-199807000-00017","article-title":"The lung and Waldenstr\u00f6m's macroglobulinemia","volume":"91","author":"Fadil","year":"1998","journal-title":"South Med J"},{"key":"2021122206320555800_R4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.35.4.603","article-title":"Waldenstr\u00f6m's macroglobulinemia and peripheral neuropathy: deposition of M-component and kappa light chain in the endoneurium","volume":"35","author":"Vital","year":"1985","journal-title":"Neurology"},{"key":"2021122206320555800_R5","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/WNL.37.9.1506","article-title":"Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins","volume":"37","author":"Nobile-Orazio","year":"1987","journal-title":"Neurology"},{"key":"2021122206320555800_R6","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3","article-title":"Waldenstr\u00f6m's macroglobulinemia: incidence patterns in the United States, 1988-1994","volume":"82","author":"Groves","year":"1998","journal-title":"Cancer"},{"key":"2021122206320555800_R7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/088506669501000304","article-title":"Hyperviscosity syndrome","volume":"10","author":"Gertz","year":"1995","journal-title":"J Intensive Care Med"},{"key":"2021122206320555800_R8","first-page":"69","article-title":"Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenstr\u00f6m and multiple myeloma: influence on blood rheology and the microcirculation","volume":"119","author":"Reinhart","year":"1992","journal-title":"J Lab Clin Med"},{"key":"2021122206320555800_R9","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1926::AID-CNCR9>3.0.CO;2-L","article-title":"Waldenstr\u00f6m's macroglobulinemia: a clinicopathologic study of 22 cases","volume":"80","author":"Andriko","year":"1997","journal-title":"Cancer"},{"key":"2021122206320555800_R10","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V83.10.2939.2939","article-title":"Study of prognosis in Waldenstr\u00f6m's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility","volume":"83","author":"Gobbi","year":"1994","journal-title":"Blood"},{"key":"2021122206320555800_R11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ajh.2830480411","article-title":"Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature","volume":"48","author":"Humphrey","year":"1995","journal-title":"Am J Hematol"},{"key":"2021122206320555800_R12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/10428199409049636","article-title":"A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal IgM gammopathy","volume":"13","author":"Rotoli","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"2021122206320555800_R13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/07357909109032794","article-title":"Waldenstr\u00f6m's macroglobulinemia: long-term results with the M-2 protocol","volume":"9","author":"Case","year":"1991","journal-title":"Cancer Invest"},{"key":"2021122206320555800_R14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(93)90231-D","article-title":"Fludarabine therapy in Waldenstr\u00f6m's macroglobulinemia","volume":"95","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"key":"2021122206320555800_R15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0609.1995.tb01779.x","article-title":"Fludarabine treatment in resistant Waldenstr\u00f6m's macroglobulinemia","volume":"54","author":"Zinzani","year":"1995","journal-title":"Eur J Haematol"},{"key":"2021122206320555800_R16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1999.17.2.546","article-title":"Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstr\u00f6m's macroglobulinemia, and mantle-cell lymphoma","volume":"17","author":"Foran","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122206320555800_R17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-118-3-199302010-00007","article-title":"Treatment of Waldenstr\u00f6m macroglobulinemia with 2-chlorodeoxyadenosine","volume":"118","author":"Dimopoulos","year":"1993","journal-title":"Ann Intern Med"},{"key":"2021122206320555800_R18","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.1994.12.12.2694","article-title":"Primary therapy of Waldenstr\u00f6m's macroglobulinemia with 2-chlorodeoxyadenosine","volume":"12","author":"Dimopoulos","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122206320555800_R19","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1093\/annonc\/7.suppl_6.S27","article-title":"Purine analogs in chronic lymphocytic leukemia and Waldenstr\u00f6m's macroglobulinemia","volume":"7","author":"O'Brien","year":"1996","journal-title":"Ann Oncol"},{"key":"2021122206320555800_R20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1365-2141.1998.01069.x","article-title":"Bolus administration of cladribine in the treatment of Waldenstr\u00f6m macroglobulinaemia","volume":"103","author":"Liu","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122206320555800_R21","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/1097-0142(19820615)49:12<2580::AID-CNCR2820491228>3.0.CO;2-5","article-title":"\u201cWaldenstr\u00f6m's macroglobulinemia\u201d terminating in immunoblastic sarcoma. A case report","volume":"49","author":"Abe","year":"1982","journal-title":"Cancer"},{"key":"2021122206320555800_R22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ajcp\/71.1.121","article-title":"Immunoblastic sarcoma following Waldenstr\u00f6m's macroglobulinemia","volume":"71","author":"Choi","year":"1979","journal-title":"Am J Clin Pathol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.5-1-63","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.5-1-63","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/1\/63\/41836991\/oncolo_5_1_63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/1\/63\/41836991\/oncolo_5_1_63.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T06:33:58Z","timestamp":1640154838000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/5\/1\/63\/6386069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2000,2,1]]},"published-print":{"date-parts":[[2000,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.5-1-63","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,2,1]]},"published":{"date-parts":[[2000,2,1]]}}}